Publicaciones (84) Publicaciones en las que ha participado algún/a investigador/a

2018

  1. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

    Cell, Vol. 175, Núm. 2, pp. 313-326

  2. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

    Nature Communications, Vol. 9, Núm. 1

  3. A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients

    Journal of Pathology, Vol. 245, Núm. 4, pp. 421-432

  4. A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1

  5. Adjuvant therapy for colon cancer: Genes, genes. . . And the patient in the center

    Clinical Cancer Research, Vol. 24, Núm. 16, pp. 3787-3789

  6. Alteraciones analíticas

    Guía inmunotoxicidad: diagnóstico y manejo de los efectos secundarios asociados a inmunoterapia en oncología (EUNSA. Ediciones Universidad de Navarra, S.A.), pp. 204-210

  7. Are phase I trials safe for older patients?

    Journal of Geriatric Oncology, Vol. 9, Núm. 2, pp. 87-92

  8. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

    Annals of Oncology, Vol. 29, Núm. 10, pp. 2121-2128

  9. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens

    European Urology, Vol. 73, Núm. 3, pp. 462-468

  10. Cardiología

    Guía inmunotoxicidad: diagnóstico y manejo de los efectos secundarios asociados a inmunoterapia en oncología (EUNSA. Ediciones Universidad de Navarra, S.A.), pp. 17-33

  11. Characterization of Macrophage Endogenous S-Nitrosoproteome Using a Cysteine-Specific Phosphonate Adaptable Tag in Combination with TiO2 Chromatography

    Journal of Proteome Research, Vol. 17, Núm. 3, pp. 1172-1182

  12. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer

    Clinical Genitourinary Cancer, Vol. 16, Núm. 6, pp. e1133-e1139

  13. Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience

    Breast Journal, Vol. 24, Núm. 4, pp. 473-479

  14. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319

  15. Correction to: SEOM clinical guidelines for endometrial cancer (2017) (Clinical and Translational Oncology, (2018), 20, 1, (29-37), 10.1007/s12094-017-1809-9)

    Clinical and Translational Oncology

  16. Corrections to “Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up” (Annals of Oncology (2013) 24(S6) (vi24–vi32), (S0923753419315613), (10.1093/annonc/mdt333))

    Annals of Oncology

  17. Dermatología

    Guía inmunotoxicidad: diagnóstico y manejo de los efectos secundarios asociados a inmunoterapia en oncología (EUNSA. Ediciones Universidad de Navarra, S.A.), pp. 36-51

  18. Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4–1BB)

    OncoImmunology, Vol. 7, Núm. 1

  19. Digestivo

    Guía inmunotoxicidad: diagnóstico y manejo de los efectos secundarios asociados a inmunoterapia en oncología (EUNSA. Ediciones Universidad de Navarra, S.A.), pp. 54-61

  20. Early evolutionary divergence between papillary and anaplastic thyroid cancers

    Annals of Oncology, Vol. 29, Núm. 6, pp. 1454-1460